Highnoon Laboratories Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0070701013
PKR
949.64
41.36 (4.55%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Highnoon Laboratories Ltd. stock-summary
stock-summary
Highnoon Laboratories Ltd.
Pharmaceuticals & Biotechnology
Highnoon Laboratories Limited is a Pakistan-based pharmaceutical company. The Company is principally engaged in the manufacture, import, sale and marketing of pharmaceutical and allied consumer products. The Company offers products for various therapeutic areas, such as alimentary tract and metabolism, cardiovascular and respiratory products. The Company's product brands for alimentary tract and metabolism include Tres Orix Forte, Ulsanic, Skilax and Tagipmet. The Company's cardiovascular portfolio includes Misar brand, which is an angiotensin receptor blocker (ARB) used in the management of hypertension. Its products include AIRTAL (Aceclofenac), which has non-steroidal, anti-inflammatory and analgesic properties; ARIA (ketotifen), a non-bronchodilator antiasthamatic drug; ARTECXCIN, which acts as a blood schizotocide, and artrodar (diacerein), used for the treatment of inflammation and rheumatism. Its other products include Asthavent, AXESOME, Bezisox and Betatec.
Company Coordinates stock-summary
Company Details
17.5 Kilometer Multan Road , LAHORE None : 53700
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Tausif Ahmed Khan
Chairman of the Board
Zainub Abbas
Director
Siddiqa Begum
Director
Mr. Romesh Elapata
Director
Baqar Hasan
Director
Ghulam Hussain Khan
Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
7,026 Million
(Quarterly Results - Mar 2025)
Net Profit:
955 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 53,905 Million (Large Cap)

stock-summary
P/E

18.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

3.93%

stock-summary
Debt Equity

-0.18

stock-summary
Return on Equity

26.44%

stock-summary
Price to Book

4.36